

# 36th EORTC-PAMM Winter Meeting

Wednesday 21-Saturday 24 January, 2015  
Amphitheater MPM, Marseille, France

## Time for paradigm shifts in oncology?



**Local Organising Committee**

Dr J. Ciccolini, *Marseille, France*

**PAMM Scientific Committee**

Pr G.J. Peters, *Amsterdam, The Netherlands*

### PRELIMINARY PROGRAM

[www.pamm2015.com](http://www.pamm2015.com)

## Wednesday the 21<sup>th</sup>, January

### 12H00-14H00 Registration & Welcome to Marseille Buffet Lunch.

### 14H00 Young Researcher-1 GPCO-Unicancer/PAMM-EORTC joint Session.

14H00 **Sergei Zakharov** Moscow, RU: change of drug resistance of acute myeloid leukemia cells in multicellular aggregates in vitro.

14H15 **Marion Peyressatre**, Montpellier FR: Fluorescent biosensor for probing CDK5 activity in neuronal cells -application to glioblastoma.

14H30 **Halabi Najeeb**, Doha QA: The significance of non-mutated genes in ovarian cancer.

14H45 **Maeva Lion**, Nancy FR: Tumor signaling alteration in her2-positive breast cancer treated by preoperative trastuzumab – everolimus.

15H00 **Aurelie Lombard**, Marseille FR: Revisiting metronomics: model-driven gemcitabine in mice with resistant neuroblastoma.

### 15H15 Coffee Break & Poster Session.

16H00 **Thierry Bastogne**, FR: In silico design of nanoparticles for the treatment of cancers by enhanced radiotherapy

16H15 **Charles Skarbek**, Paris FR: New strategies for better therapeutic index of ifosfamide.

16H30 **Damien Reita**, Strasbourg FR: Targeting oncogenic pathways and HIF-1 $\alpha$  in colon tumors by combination of irinotecan and mTOR inhibitors of new generation.

16H45 **Yuliya Chernykh**, Moscow RU: Multidrug resistance genes expression in refractory multiple myeloma patients.

17H00 **Paul Mesange**, Paris FR: Treatment with Nintedanib, a selective triple angiokine inhibitor, is accompanied by activation of EGFR and other EGFR-family members in colorectal cancer (CRC) xenografts, providing a rationale for combination of nintedanib with the EGFR-family inhibitors

17H15 **Fabienne Thomas**, Toulouse FR: Lethal toxicity of 5-fluorouracil in the era of personalized therapy: discovery of a novel mutation disrupting the dihydropyrimidine deshydrogenase activity.

### 17H30 What's in The Pipe?

17H30 **Gerard Milano**, Nice FR: Novel Strategies in melanoma.

17H50 **Régis Costello**, Marseille FR: Current Advances in Hematology.

18H10 **Fabrice Barlesi**, Marseille FR: The 5 next pathways to be targeted in lung cancer.

### 18H30-20H00 Welcome to Marseille Cocktail Reception

## Thursday the 22d, January

**8H30 PAMM-2015 Opening – GJ Peters, Amsterdam NL & J Ciccolini Marseille FR.**

**9H00 Metronomics.**

9H00 **Nicolas André**, Marseille FR: Metronomics in 2015: What for?

9H20 **Urzula Ledzewicz**, Edwardsville USA: What can Modeling and simulation tell us about optimality of metronomic chemotherapy?

9H40 **Eddy Pasquier**, Randwick AUS: Metronomics or how to make chemotherapy sexy.

**10H Coffee break & Poster Session.**

**10H30 What's In the pipe?**

10H30 **Fabrice André**, Villejuif FR: Bioguided Therapy in Breast Cancer.

**10H50 Modeling & Simulation Session-1.**

10H50 **Jennifer Bonner**, Newcastle UK: building special populations into PBPK models: focus on paediatrics and the elderly.

11H10 **Christophe Chassagnole**, Oxford UK: Translational modelling of vemurafenib, selumetinib and docetaxel in metastatic melanoma with virtual tumour.

11H30 **Sebastien Benzekry**, Bordeaux FR: A translational in vivo/in silico quantitative modeling study of the impact of surgery on metastatic relapse and survival in breast cancer

**11H50 Buffet Lunch & Poster Session.**

**13H-14H: BMS Symposium: Challenges and perspectives of immuno-oncology**

**14H00 Nanotechnologies & Drug Delivery.**

14H00 **Patrick Couvreur**, Paris FR: Nanomedicine: a new approach for the treatment of severe diseases.

14H25 **William Zamboni** : Chapel Hill USA: Translational studies evaluating the bi-directional interaction between carrier-mediated anticancer agents and the mononuclear phagocyte system

14H50 **Jean-Pierre Benoit**, Angers FR: The lipid nanocapsules: a versatile nanomedicine for chemo and radiotherapy.

15H15 **Simona Mura**, Paris FR: peptide-functionalized nanoparticles for selective targeting of pancreatic tumors.

**15H35: Coffee Break & Poster Session.**

**16H05: Modelling & Simulation Session-2.**

16H05 **Coen Van Hasselt** Leiden NL: Impact of modelling & simulation in pediatric oncology.

16H25 **Markus Jörger** St Gallen CH: Implementation of therapeutic drug monitoring and dosing algorithms in patients with solid malignancies: A focus on taxanes.

16H 45 **Antonello DiPaolo**, Pisa IT: Integrated approaches in discovering predictive biomarkers of BCR-Abl inhibitors in Chronic Myeloid Leukemia.

17H05 **Dominique Barbolosi**, Marseille FR: Integrating Modelling & Simulation tools into clinical practice.

17H25 **Chantal Csajka**, Lausanne CH: From PK Modelling to Bayesian adaptive dosing of targeted therapies.

**17H45: Coffee Break and Poster Session**

**18H30: coach departure - PAMM indoor Football match.**

**Free Evening!**

## Friday the 23d, January

### 8H30 Burger-Kelland PAMM Lecture.

**Hillary Calvert** London UK: In search of truly selective anticancer treatments: Does PAMMacokinetics help?

### 9H00 Bioguided Therapy.

9H00 **Howard McLeod**, Tampa USA: Pharmacogenomics as part of probabilistic patient management.

9H20 **Annette Larsen**, Paris FR: Overcoming bevacizumab-induced survival signaling in colorectal cancer: from bench to phase III.

9H40 **David Planchard**, Villejuif FR: bio-guiding the use of immunecheckpoints in NSCLC.

10H00 **Olivier Adotevi**, Besançon FR: Telomerase-derived universal cancer peptides : a novel prognosis biomarker to monitor CD4 TH1 immunity in cancer patients.

### 10H20 Coffee Break & Poster Session

### 11H00 Translational-1.

11H00 **Adriana Albini** IT: The shifting target in the paradigm shift: heterogeneity of cancer cells and the tumor microenvironment.

10H20 **Yehuda Assaraf**, Haifa IL: Lysosomal sequestration of chemotherapeutics triggers lysosomal biogenesis and lysosome cancer multidrug resistance.

11H40 **David Cox**, Lyon FR: Translation of genetic polymorphisms to the clinic.

### 12H00 Buffet Lunch & Poster Session.

### 13H-14H: AMGEN Symposium: Advances in Biotherapies.

### 14H00 What's in The Pipe?

14H00 **Marc Ychou** Montpellier FR: Advances in Digestive Oncology.

### 14H15 EORTC session.

14H15 **Frits Peters**, Amsterdam NL : Drug development at the EORTC-Drug Discovery Committee : what can we learn from successful examples

### 15H00 Translational -2.

15H00 **May Morris**, Montpellier FR: Fluorescent Peptide Biosensors for probing kinase activities – new tools for cancer diagnostics and drug discovery.

15H20 **Nikolai Tupitsyn**, Moscow RU: The clinical significance of the analysis lymphocyte subsets in the bone marrow rhabdomyosarcoma and Ewing's sarcoma family in children.

15H40 **Annemilei Raballand**, Paris FR: Ex-vivo cultures of freshly expanded tumors: a potent translational approach for screening novel targeted therapies.

### 16H00 Coffee Break & Poster Session.

### 16H30 Translational -2 (cont'd)

16H30 **Maria Rivera** Berlin GER: Colorectal Cancer derived (PDX) models as platform for drug screen, molecular and biomarker analysis.

16H50 **Duncan Jodrell**, Cambridge UK: Translational therapeutics research in patients with pancreatic cancer.

17H10 **Wolfgang Walther**, Berlin GER: Targeted therapy of claudin-3 and -4 expressing human pancreatic tumors by Clostridium perfringens enterotoxin (CPE) gene transfer.

### 17H30 Omics & Imaging.

17H30 **Daniel Lafitte**, Marseille FR: revisiting cancer pharmacology by MALDI-imaging.

17H50 **Norbert Lutz**, Marseille FR: Simulating Multiparametric Analysis of Tissue Heterogeneity - A Novel Paradigm for Quantifying Tumor pH and Other Metabolic Parameters

### 18H10 PAMM-2016 Announcement & Poster Session.

### 20H00 PAMM-2015 Social Event.

## Saturday the 24th, January

### 9H00 Young Researcher-2.

9H00 **Swantje Völler**, Munster GER: Analysis of Biomarkers for Anthracycline Induced Cardiotoxicity in Children.

9H15 **Anaïs Bouygues**, Paris FR: VEGF-directed therapies directly attenuate the migration of both chemo-naïve and 5-fluorouracil resistant colorectal cancer cells.

9H30 **Chris Walsh**, Newcastle UK: Use of a physiologically-based pharmacokinetic modelling and simulation approach to rationalise actinomycin D dosing in paediatric oncology.

9H45 **Maria Stecklum**, Berlin GER: Humanized mice – a suitable model to study immunotherapeutics for cancer therapy in vivo.

### 10H00 Coffee Break & Poster Session

10H45 **Majus Missiak**, Gdansk PL: Asymmetrically substituted anthrapyridazones - a novel group of DNA topoisomerase inhibitors with potent activity against human tumors.

11H00 **Chloé Sauzay**, Toulouse FR: Inhibition of OCT-2, MATE1 and MATE-2K as a possible mechanism of drug interaction between pazopanib and cisplatin.

11H15 **Mohannad Qazzaz**, Nottingham UK: Activity and mechanisms of action of Jerantinine B

11H30 **Dunja Sobot**, Paris FR: gemcitabine-squalene nanoparticles and plasma lipoproteins: role in anticancer activity.

11H45 **Nicola Funel**, Amsterdam NL and Pisa IT: CYB5A emerges as a prognostic factor from –omics studies in pancreatic cancer, and preclinical studies in novel patient-derived experimental models unravel its role in the modulation of autophagy and oncogenic phenotypes.

**12H00: Awards and Closing remarks –GJ Peters Amsterdam, NL and E. Raymond, Lausanne CH.**

**12H30-14H: Farewell Buffet Lunch.**

## Poster session

- **Wednesday 21<sup>st</sup> January: 12H-14H, 15H15-16H, 18H30-20H.**
- **Thursday 22d January: 10H-10H30, 12H-14H, 15H35-16H05, 17H40-19H.**
- **Friday 23d January: 10H20-11H, 12H-14H, 16H-16H30, 18H15-19H.**
- **Saturday 24<sup>th</sup> January: 10H-10H45.**

**Ahmed Al-Kattan**, Marseille FR: Silicon nanoparticles synthesized by laser ablation: Study of the biological properties in vitro for theranostic applications in cancer therapy.

**Lamia Amrane**, Alger AL: Giant-cell tumor of bone: a case report of neoadjuvant use of denosumab RANKL inhibitor.

**Lamia Amrane**, Alger AL: Uterine sarcoma and breast cancer: a Case report.

**Amalia Azzariti**, Bari IT: A novel therapeutic approach for the treatment of Hodgkin Lymphoma: in vitro study.

**Dominique Barbolosi**, Marseille FR: Modelling prognostic markers at bedside: application to forecasting biomarkers evolution and to revisiting imaging in clinical oncology.

**Manon Carré**, Marseille Fr: Metronomic scheduling: a promising strategy to manage intratumor heterogeneity and to control resistance.

**Florian Correard**, Marseille FR: New paclitaxel-dendrimer complexes for cancer therapy.

**Galina Dudina**, Moscow RU: Clinical Efficacy of Azacitidine in Patients with Myelodysplasia Syndrome.

**Nicolas Fabresse**, Marseille FR: 7-hydroxymethotrexate: An early marker of methotrexate delayed elimination in pediatric patients?

**Sabrina Falkowski**, Limoges FR: Common variants in glucuronidation enzymes and membrane transporters as risk factors for colorectal cancer: a case-control study.

**Florence Gattacceca**, Montpellier, FR: Pharmacokinetics of nanoparticles for anticancer drugs delivery: review of analysis methods and parameter values.

**Manel Hadidane** : Chromophobe renal cell carcinoma: about 6 cases.

**Richard Honeywell**, Amsterdam NL: Whole body pharmacokinetics of crizotinib in a mouse model.

**Stéphane Honoré**, Marseille FR: Modeling the effects of EB1 and vincristine action on microtubule dynamic instability in glioblastoma cells: An explanation for EB1 sensitization to microtubule targeting drugs.

**Julia Horilova**, Tartu, EST: Time-resolved autofluorescence imaging of cancer.



**Geritt Jansen**, Amsterdam, NL: Carboxylesterase-1 colocalization with lipid droplets is implicated in conversion and biological activity of a hydrophobic aminopeptidase inhibitor prodrug in myeloid (leukemia) cells.

**Markus Joerger**, St Gallens CH: Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).

**Umesh Kalathiya**, Gdansk PL: Identification of potent telomerase inhibitors for cancer therapy using in silico docking studies.

**Sara Karaki**, Marseille FR: Targeting Translationally controlled Tumor protein TCTP signaling pathway as a therapeutic Strategy in Castration-resistant Prostate Cancer.

**Aida Karamysheva**, Moscow RU: Survival of multiple myeloma patients is different in groups with various intensities of vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) mRNA co-expression.

**Marion Le Grand**, Marseille Fr: Combining microtubule-targeting agents & anti-Akt: a promising therapeutic strategy?

**Bertrand Le Roy**, FR: Relationship between the expression of organic cation transporters in colorectal cancer and the response to FOLFOX chemotherapy: a case control, monocentric and retrospective study.

**Andrey Maksimenko**, Paris, FR: Squalenoyl doxorubicin nanoassemblies: a unique “spaghetti-like” anticancer nanomedicine.

**Andrey Maksimenko**, Paris, FR: Therapeutic Modalities of Squalenoyl Nanocomposites in Colon Cancer.

**Christophe Meille**, Marseille FR: Computational-driven regimen in metastatic breast cancer patients: the Model-1 study.

**Tatyana Mitina**, Moscow RU: FOXP 3 expression and its isoforms in peripheral blood of patients with multiple myeloma.

**Angelina Molina Crespo**, Madrid, SP: Developing antibody-loaded hyaluronic acid nanocapsules as a new therapeutic strategy in breast carcinoma cells.

**Halabi Najeeb**, Doha QA: Identifying Germline and Somatic Driver Gene Variants in Epithelial Ovarian Cancer Samples.

**Jean-Michel Nguyen**, Nantes FR: Method for identifying subjects with a ghost prognostic factor.

**Eddy Pasquier**, Marseille FR: High-throughput screening based on drug repositioning principles identifies new therapeutic targets in neuroblastoma.

**Marzia Pennati**, Milano IT: In Vitro Antiproliferative Activity And Molecular Mechanism(S) Of Action Of Novel Water-Soluble Isoindolo[2,1-A]Quinoxalin-6-Imines.

**Paola Perego**, Milano IT: Role of the receptor tyrosine kinase Axl in the aggressive features of platinum-resistant ovarian carcinoma cells.

**Jean Piechowski**, Paris FR: Phenotypic hybridization of the malignant cell

**Jacques Robert**, Bordeaux FR: Cytochrome P450 1B1 as a determinant of cell proliferation and motility in head-and-neck carcinoma.

**Michelle Sabbah**, Paris FR: Chronic chemotherapeutic stress promotes evolution of stemness and WNT/beta-catenin signaling in colorectal cancer cells: implications for clinical use of WNT signaling inhibitors.

**Marcin Serocki**, Gdansk, PL: Novel functionalized conjugates of batracylin with aminoacids and short peptides as new antitumor agents.

**Jana Rolff**, Berlin GER: PDX of soft tissue sarcomas as preclinical models for the prediction of therapy resistance.

**Dzjemma Sarkisjan**, Amsterdam NL: Radiosensitization by TAS-102 of colorectal cancer cells.

**Cindy Serdjeji**, Marseille FR: Pharmacogenetics of gemcitabine: Where did we go wrong?

**Annemiläi Tijeras-Raballand**, Clichy FR: Galunisertib combined with sorafenib affects proliferation, EMT and delays tumor growth in mice and in patient samples ex vivo.

**Fabienne Thomas**, Toulouse FR: Lethal toxicity of 5-fluorouracil in the era of personalized therapy: discovery of a novel mutation disrupting the dihydropyrimidine deshydrogenase activity.

**Elena Trifonova**, Moscow RU: Clinical Efficacy of Dasatinib in the Second-line Therapy of Patients with Chronic Myeloid Leukemia.

**Laure-Anais Vincent**, Montpellier, FR: Lysosomes, unfolded protein response and autophagy as potential determinants of malignant melanoma differential resistance to vinca-alkaloids.

**Liudmila Vysotskaya**, Moscow RU: Efficacy of Intermittent Imatinib Therapy in Patients with Chronic Myeloid Leukemia is the Real Basis of Routine Clinical Practice.

## CONTACT & REGISTRATION

### Com & Co Events

Etienne Jarry

Tél. :+33 (0)4 91 09 70 53

[ejarry@comnco.com](mailto:ejarry@comnco.com)